SLC5A2 and diabetic kidney disease: While the central theme of this narrative review is to discuss the role of newtherapies (ie, SGLT2 inhibitors, finerenone) in the management of DKD, it iscritical to reinforce the continued importance of the historic standard of care(glycemic control, BP control, and RAAS blockade).